JNJ-38518168 + methotrexate

JNJ-38518168 + methotrexate is an investigational combination therapy used in clinical trials for the treatment of active rheumatoid arthritis and other inflammatory conditions. JNJ-38518168 (toreforant) is a selective, oral antagonist of the *histamine H4 receptor*, developed to modulate immune cell activity and reduce inflammation. Methotrexate is an established antimetabolite and immunosuppressant used as a first-line disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis. The combination was studied to understand pharmacokinetics, safety, and efficacy in patients who had an incomplete response to methotrexate monotherapy, targeting enhanced disease control by adding an H4 receptor antagonist to methotrexate therapy.

Brand names

Toreforant

Other names

toreforant + methotrexate